已收盘 01-09 16:00:00 美东时间
0.000
0.00%
Abivax has announced a $650 million public offering of American Depositary Shares (ADSs), each representing one ordinary share. The offering is priced at $64.00 per ADS, with proceeds to be used primarily for clinical development of obefazimod for Ulcerative Colitis and Crohn’s Disease, as well as general corporate purposes. The offering may dilute existing shareholders by up to 18.4%. Risks include immediate dilution, future sales depressing sha...
07-24 12:40